Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prostate cancer

Credit: Gary Neill

Live long enough, and most men will develop prostate cancer. Globally, it is the second most common cancer in men, and in some places it takes the top spot (page S118).

As the prime reproductive years fade, the gland typically begins to misbehave. The first sign that men often experience is inflammation — a condition that is sometimes, but not always, a precursor to cancer. The interplay between inflammation and cancer remains an area of intense research (page S130).

Prostate-cancer screening has provoked contentious debate (page S120). Blood tests for prostate-specific antigen (PSA) have led to the discovery of cancers at earlier and more treatable stages. But they have also revealed many tumours that could safely be left untreated. Researchers are looking beyond PSA to other biomarkers that could be used to tell more reliably which cancers need treatment (page S124). Often, the best therapeutic option is just to be vigilant — 'active surveillance' is now the norm (page S126). When a trip to the operating theatre is unavoidable, robotics is making prostate surgery less likely to cause adverse effects (page S132).

Hopes for a vaccine have dimmed (page S134). The only approved immunotherapy for prostate cancer — sipuleucel-T — adds mere months to survival time and is expensive. Researchers are focusing on combinations of therapies, such as a checkpoint therapy administered together with a drug that targets tumour hypoxia. Because prostate tumours are most dangerous once they escape the gland itself, intense efforts are targeting metastatic cancers that have become resistant to standard treatments (page S128).

We are pleased to acknowledge support from Ferring Pharmaceuticals and a grant from Astellas Pharma Global Development, Inc. and Medivation, Inc. in producing this Outlook. As always, Nature retains sole responsibility for all editorial content.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brody, H. Prostate cancer. Nature 528, S117 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing